Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency.
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…
